{"title":"[Peritoneal dialysis in treatment of end-stage renal disease].","authors":"Séverine Beaudreuil","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>PERITONEAL DIALYSIS IN THE TREATMENT OF END-STAGE RENAL DISEASE. Peritoneal dialysis (PD) is a replacement therapy for patients with stage 5 chronic kidney disease (CKD5). Its use varies from country to country. In France, only 11% of CKD5 patients are treated with PD, with great disparity between regions, the majority being supported with center hemodialysis (HD). Yet this treatment offers many advantages. It is a home-based treatment, allowing greater autonomy, and easy for patients to learn. In the event of incapacity, assistance can be provided by a nurse or a relative. No vascular approach is required. Its effectiveness in terms of patient survival is at least identical to that of HD patients. It is vital that all patients at MRC4 or 5 stage should be managed within the care pathway recommended by Haute Autorité de santé, so that they can benefit, among other things, from informed pre-dialysis information on the different dialysis modalities.</p>","PeriodicalId":94123,"journal":{"name":"La Revue du praticien","volume":"74 9","pages":"935-941"},"PeriodicalIF":0.0000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"La Revue du praticien","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
PERITONEAL DIALYSIS IN THE TREATMENT OF END-STAGE RENAL DISEASE. Peritoneal dialysis (PD) is a replacement therapy for patients with stage 5 chronic kidney disease (CKD5). Its use varies from country to country. In France, only 11% of CKD5 patients are treated with PD, with great disparity between regions, the majority being supported with center hemodialysis (HD). Yet this treatment offers many advantages. It is a home-based treatment, allowing greater autonomy, and easy for patients to learn. In the event of incapacity, assistance can be provided by a nurse or a relative. No vascular approach is required. Its effectiveness in terms of patient survival is at least identical to that of HD patients. It is vital that all patients at MRC4 or 5 stage should be managed within the care pathway recommended by Haute Autorité de santé, so that they can benefit, among other things, from informed pre-dialysis information on the different dialysis modalities.